Regenicin (OTCMKTS:RGIN) and Lyra Therapeutics (NASDAQ:LYRA) Head to Head Contrast

Lyra Therapeutics (NASDAQ:LYRA) and Regenicin (OTCMKTS:RGIN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations and earnings.

Profitability

This table compares Lyra Therapeutics and Regenicin’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lyra Therapeutics	-6,635.76%	-125.07%	-59.74%
Regenicin	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Lyra Therapeutics and Regenicin, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyra Therapeutics	1	4	1	0	2.00
Regenicin	0	0	0	0	0.00

Lyra Therapeutics currently has a consensus price target of $4.50, suggesting a potential upside of 1,983.33%. Given Lyra Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Lyra Therapeutics is more favorable than Regenicin.

Institutional and Insider Ownership

95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 0.0% of Regenicin shares are held by institutional investors. 4.7% of Lyra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Lyra Therapeutics has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500. Comparatively, Regenicin has a beta of -18.91, meaning that its share price is 1,991% less volatile than the S&P 500.

Valuation & Earnings

This table compares Lyra Therapeutics and Regenicin”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyra Therapeutics	$1.47 million	9.61	-$62.68 million	($1.49)	-0.14
Regenicin	N/A	N/A	-$640,000.00	N/A	N/A

Regenicin has lower revenue, but higher earnings than Lyra Therapeutics.

Summary

Lyra Therapeutics beats Regenicin on 7 of the 11 factors compared between the two stocks.

About Lyra Therapeutics

Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

About Regenicin

Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Its product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. The company products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.